OBJECTIVE： To investigate the effects of Shenfukang capsules on clinical efficacy and renal function indexes of patients with renal insufficiency. METHODS： Totally 100 inpatients with renal insufficiency treated by Shenfukang capsules in the First Affiliated Hospital of Guangxi Medical University during Feb. to Mar. 2015 were analyzed retrospectively in respects of general information of patients， therapy plan， renal function indexs before and after treatment and clinical efficacy. The relationship of clinical efficacy with age and duration was also analyzed. RESULTS： There were 33 cases of acute renal insufficiency and 67 cases of chronic renal insufficiency. The route of administration of Shenfukang capsules was oral administration （97 cases， 97.00％）， the main dosage was 6 capsule/d （36 cases， 36.00％）， and treatment duration were 0-＜7 days （39 cases） and 7-＜15 days （49 cases）. After treatment， the average serum creatinine concentration was lower than before treatment， while mean GFR and Ccr were higher than before treatment， with statistical significance （P＜0.05）. The total response rate was 72.00％， and response rate of patients with acute renal insufficiency was 87.88％ and significantly higher than 64.18％ of patients with chronic renal insufficiency， with statistical significance（P＜0.05）. Among patients with ≤60 years old， the total response rate of patients with acute renal insufficiency was significantly higher than that of patients with chronic renal insufficiency， with statistical significance（P＜0.05）； among patients elder than 60 years old， there was no statistical significance in therapeutic efficacy between acute renal insufficiency and chronic renal insufficiency （P＞0.05）； among patients with chronic renal insufficiency， the total response rate  of patients elder than 60 years old was significantly better than that of patients with ≤60 years old， with statistical significance （P＜0.05）. With the extension of treatment duration， the total response rate of patients with acute renal insufficiency was on the rise， and that of patients with chronic renal insufficiency increased first and then decreased. No obvious ADR was found during treatment. CONCLUSIONS： Shenfukang capsules can improve renal function in patients with renal insufficiency， and has definite curative effect on acute and chronic renal insufficiency with good security. The clinical efficacy may be related to age and treatment course.